Elamipretide – Talk Bio

Actionable Insights Powered by AI

FDA Delays Decision on Stealth BioTherapeutics’ Elamipretide for Barth Syndrome Until April 2025

3 months ago talkbio0Tagged 3-Methylglutaconic aciduria type 2, Decision, Drug Approval, Elamipretide, Stealth BioTherapeutics, United States Food and Drug Administration

Barth Syndrome, Elamipretide, FDA Decision, Stealth BioTherapeutics, Drug Approval Delay

FDA Advisory Committee Supports Stealth BioTherapeutics’ Elamipretide for Barth Syndrome Despite Data Concerns

6 months ago talkbio0Tagged 3-Methylglutaconic aciduria type 2, Advisory Committees, Elamipretide, Stealth BioTherapeutics, ultra-rare disease, United States Food and Drug Administration, unmet

Stealth BioTherapeutics, elamipretide, Barth syndrome, FDA advisory committee, ultra-rare disease, unmet medical need

FDA Raises Concerns Over Stealth BioTherapeutics’ Ultra-Rare Disease Drug Ahead of Advisory Committee Meeting

7 months ago talkbio0Tagged 3-Methylglutaconic aciduria type 2, Advisory Committees, concerns, Drug Approval, Effectiveness, Elamipretide, Stealth BioTherapeutics, ultra-rare disease, United States Food and Drug Administration

FDA, Stealth BioTherapeutics, elamipretide, Barth syndrome, ultra-rare disease, advisory committee meeting, drug approval, efficacy concerns

FDA Raises Concerns Over Stealth BioTherapeutics’ Ultra-Rare Disease Drug Approval

7 months ago talkbio0Tagged 3-Methylglutaconic aciduria type 2, Approved, Elamipretide, Stealth BioTherapeutics, United States Food and Drug Administration

Stealth BioTherapeutics, ultra-rare disease, FDA approval, Barth syndrome, elamipretide